Comparative Pharmacology
Head-to-head clinical analysis: EXBLIFEP versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXBLIFEP versus NEO FRADIN.
EXBLIFEP vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exblifep is a beta-lactamase inhibitor combination consisting of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. Enmetazobactam inhibits Ambler class A and some class C beta-lactamases, restoring cefepime activity against beta-lactamase-producing Enterobacterales.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
2.5 g (cefepime 2 g, enmetazobactam 0.5 g) intravenously every 8 hours infused over 2 hours.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
The terminal elimination half-life of Exblifep is approximately 8-10 hours in patients with normal renal function. In patients with renal impairment, half-life is prolonged and dosing adjustments are required.
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Exblifep is primarily excreted renally as unchanged drug (approximately 60-70% of the dose) and as the active metabolite nifepristone (approximately 20-30%). Fecal excretion accounts for <10% of the dose. Biliary excretion is minimal.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic
Antibiotic